Date | Title | Description | |
---|---|---|---|
23 Feb 2022 | On business and financial situation | The Company releases the press release related to the full year 2021 financial results | Download |
23 Feb 2022 | On business and financial situation | The Company releases the full year 2021 financial results presentation | Download |
23 Feb 2022 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
22 Feb 2022 | On buy-back programmes | ROVI reports the end of the share buy-back programme, effective as of 3 November 2021, and the launching of a new share buy-back programme, effective as of 23 February 2022. | Download |
16 Feb 2022 | On business and financial situation | Moderna and ROVI announced that they expand their long-term collaboration for the manufacture of mRNA medicines over the next ten years | Download |
Pages
Date | Title | Description | |
---|---|---|---|
05 Nov 2021 | Share buy-back , stabilisation and treasury stock programmes | Share Buyback Program: transactions conducted on 3 and 4 November | Download |
03 Nov 2021 | On business and financial situation | The Company releases the first nine months 2021 financial results presentation | Download |
03 Nov 2021 | On business and financial situation | The Company releases the press release related to the first nine months 2021 financial results | Download |
21 Oct 2021 | Liquidity and counterparty agreements | Download | |
21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
Pages
Date | Title | Description | |
---|---|---|---|
09 Oct 2015 | Otros sobre operaciones corporativas | Download | |
08 Oct 2015 | Otros sobre operaciones corporativas | Download | |
30 Jul 2015 | Información sobre resultados (2) | Download | |
30 Jul 2015 | Información sobre resultados | Download | |
30 Jun 2015 | Información sobre dividendos | Download |